SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-19-017687
Filing Date
2019-09-11
Accepted
2019-09-11 10:37:21
Documents
4
Period of Report
2019-09-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k090519_immucellcorp.htm 8-K 24300
2 PRESS RELEASE OF THE COMPANY DATED SEPTEMBER 11, 2019 f8k090519ex99-1_immucellcorp.htm EX-99.1 13827
3 DEVELOPMENT SERVICES AND COMMERCIAL SUPPLY AGREEMENT BETWEEN THE COMPANY AND NOR f8k090519ex99-2_immucellcorp.htm EX-99.2 118919
4 TERMINATION AGREEMENT BETWEEN THE COMPANY AND NORDSON CORPORATION DATED SEPTEMBE f8k090519ex99-3_immucellcorp.htm EX-99.3 8181
  Complete submission text file 0001213900-19-017687.txt   166380
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 191087506
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Assistant Director 1